First Affirmative Financial Network Lowers Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

First Affirmative Financial Network lessened its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.3% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,018 shares of the medical research company’s stock after selling 26 shares during the period. First Affirmative Financial Network’s holdings in Thermo Fisher Scientific were worth $1,004,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the stock. Congress Asset Management Co. lifted its position in shares of Thermo Fisher Scientific by 23.5% during the 1st quarter. Congress Asset Management Co. now owns 167,749 shares of the medical research company’s stock valued at $83,472,000 after buying an additional 31,894 shares in the last quarter. Impact Capital Partners LLC lifted its position in shares of Thermo Fisher Scientific by 7.3% during the 1st quarter. Impact Capital Partners LLC now owns 1,024 shares of the medical research company’s stock valued at $510,000 after buying an additional 70 shares in the last quarter. Chemistry Wealth Management LLC lifted its position in shares of Thermo Fisher Scientific by 77.3% during the 1st quarter. Chemistry Wealth Management LLC now owns 1,023 shares of the medical research company’s stock valued at $509,000 after buying an additional 446 shares in the last quarter. Pines Wealth Management LLC lifted its position in shares of Thermo Fisher Scientific by 8.3% during the 1st quarter. Pines Wealth Management LLC now owns 2,613 shares of the medical research company’s stock valued at $1,300,000 after buying an additional 200 shares in the last quarter. Finally, Eagle Rock Investment Company LLC lifted its position in shares of Thermo Fisher Scientific by 0.3% during the 1st quarter. Eagle Rock Investment Company LLC now owns 7,489 shares of the medical research company’s stock valued at $3,727,000 after buying an additional 26 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on TMO shares. The Goldman Sachs Group set a $610.00 price objective on Thermo Fisher Scientific and gave the company a “buy” rating in a research note on Wednesday, April 23rd. Citigroup reduced their price objective on Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. Evercore ISI reduced their price objective on Thermo Fisher Scientific from $585.00 to $500.00 and set an “outperform” rating for the company in a research note on Thursday, April 24th. Stifel Nicolaus reduced their price objective on Thermo Fisher Scientific from $665.00 to $620.00 and set a “buy” rating for the company in a research note on Thursday, April 24th. Finally, Barclays reduced their price objective on Thermo Fisher Scientific from $620.00 to $475.00 and set an “equal weight” rating for the company in a research note on Thursday, April 10th. Four equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $605.30.

Thermo Fisher Scientific Stock Up 0.9%

Shares of NYSE:TMO opened at $401.99 on Friday. Thermo Fisher Scientific Inc. has a 12-month low of $390.50 and a 12-month high of $627.88. The company has a market capitalization of $151.75 billion, a price-to-earnings ratio of 24.32, a PEG ratio of 2.99 and a beta of 0.78. The business has a 50-day moving average price of $420.74 and a 200 day moving average price of $495.93. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating analysts’ consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The business had revenue of $10.36 billion during the quarter, compared to analysts’ expectations of $10.23 billion. During the same period last year, the business earned $5.11 earnings per share. The business’s revenue for the quarter was up .2% on a year-over-year basis. Sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Friday, June 13th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 0.43%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.09%.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 3,775 shares of Thermo Fisher Scientific stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $532.52, for a total value of $2,010,263.00. Following the completion of the transaction, the senior vice president now directly owns 10,816 shares of the company’s stock, valued at $5,759,736.32. The trade was a 25.87% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the transaction, the executive vice president now directly owns 23,167 shares of the company’s stock, valued at approximately $9,960,188.31. This represents a 1.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.